Interim Report, January-June 2014

I am satisfied with our performance during the second quarter as we have continued to deliver healthy organic growth. Sales were up 6% in the second quarter, corresponding to organic growth of 4%. The EBITDA margin was 28.6% in Q2 and 29.3% for the first half year 2014. This is an improvement of 0.8%-points compared to the same period last year.

This website is intended for people seeking information on Meda Pharmaceuticals in the UK.
Links to Meda global affiliates can be found under Meda worldwide at the top of the page. For information on clinical trials please email